Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,064.20 +45.81 (+0.91%) Dow
38,225.66 +322.37 (+0.85%) Nasdaq
15,840.96 +235.48 (+1.51%) Bitcoin USD
58,727.68 +1,491.68 (+2.61%) CMC Crypto 200
1,277.10 +6.36 (+0.50%)
AMGN Jan 2025 155.000 put
| Previous close | 0.7000 |
| Open | 1.0300 |
| Bid | 0.4000 |
| Ask | 2.2200 |
| Strike | 155.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.7000 - 0.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 234 |
PR NewswireAMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024.
ReutersAmgen investors await weight-loss drug data
(Reuters) -Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly earnings on Thursday. Amgen has said it expects to have first-in-human results from a small, early-stage trial of experimental oral compound AMG786 before the end of June. "We are still collecting and analyzing the data," Amgen Chief Scientific Officer Jay Bradner told Reuters in an interview.
PR NewswireAMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego. Thirteen abstracts supporting two approved medicines and one investigational treatment will be presented.
